322 related articles for article (PubMed ID: 35682627)
1. Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors.
Ikeda D; Chi S; Uchiyama S; Nakamura H; Guo YM; Yamauchi N; Yuda J; Minami Y
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682627
[TBL] [Abstract][Full Text] [Related]
2. Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR-ABL1, a Swedish population-based study.
Orsmark-Pietras C; Landberg N; Lorenz F; Uggla B; Höglund M; Lehmann S; Derolf Å; Deneberg S; Antunovic P; Cammenga J; Möllgård L; Wennström L; Lilljebjörn H; Rissler M; Fioretos T; Lazarevic VL
Genes Chromosomes Cancer; 2021 Jun; 60(6):426-433. PubMed ID: 33433047
[TBL] [Abstract][Full Text] [Related]
3. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.
Boddu PC; Kadia TM; Garcia-Manero G; Cortes J; Alfayez M; Borthakur G; Konopleva M; Jabbour EJ; Daver NG; DiNardo CD; Naqvi K; Yilmaz M; Short NJ; Pierce S; Kantarjian HM; Ravandi F
Cancer; 2019 Apr; 125(7):1091-1100. PubMed ID: 30521114
[TBL] [Abstract][Full Text] [Related]
4. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
[TBL] [Abstract][Full Text] [Related]
5. Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases.
Fang H; Yabe M; Zhang X; Kim Y; Wu X; Wei P; Chi S; Zheng L; Garcia-Manero G; Shao L; Yuan J; Shen Y; Zheng G; Tang G; Wang W; Loghavi S; Shen Q; Yuan Y; He R; Chen D; Medeiros LJ; Hu S
Mod Pathol; 2021 Jun; 34(6):1143-1152. PubMed ID: 33558656
[TBL] [Abstract][Full Text] [Related]
6. MDM2- and FLT3-inhibitors in the treatment of
Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T
Haematologica; 2018 Nov; 103(11):1862-1872. PubMed ID: 29976747
[TBL] [Abstract][Full Text] [Related]
7. Identifying prognostic gene panels in acute myeloid leukemia.
Sanchez-Garcia J; Serrano J; Prados de La Torre E; Serrano-López J; Aparicio-Perez C; Barragán E; Montesinos P
Expert Rev Hematol; 2023 Apr; 16(4):277-287. PubMed ID: 36951195
[TBL] [Abstract][Full Text] [Related]
8. Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.
Gondran C; Dumas PY; Bérard E; Bidet A; Delabesse E; Tavitian S; Leguay T; Huguet F; Borel C; Forcade E; Vergez F; Vial JP; Rieu JB; Lechevalier N; Luquet I; Canali A; Klein E; Sarry A; de Grande AC; Pigneux A; Récher C; Largeaud L; Bertoli S
Blood Cancer J; 2024 May; 14(1):91. PubMed ID: 38821940
[TBL] [Abstract][Full Text] [Related]
9. Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.
Lo MY; Tsai XC; Lin CC; Tien FM; Kuo YY; Lee WH; Peng YL; Liu MC; Tseng MH; Hsu CA; Chen JC; Lin LI; Sun HI; Chuang YK; Ko BS; Tang JL; Yao M; Chou WC; Hou HA; Tien HF
Am J Hematol; 2023 May; 98(5):760-769. PubMed ID: 36861732
[TBL] [Abstract][Full Text] [Related]
10. Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation.
Chiriches C; Nicolaisen N; Wieske M; Elhaddad H; Mehmetbeyoglu E; Alvares C; Becher D; Hole P; Ottmann OG; Ruthardt M
PLoS Genet; 2022 Oct; 18(10):e1010463. PubMed ID: 36288392
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of Genomic Landscape in Patients with Acute Myeloid Leukemia].
Wang SM; Zheng HJ; Tian Y; Zhang JM; Yao JH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):797-801. PubMed ID: 32552938
[TBL] [Abstract][Full Text] [Related]
12. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis of rare subtypes of acute myeloid leukaemia and related neoplasms.
George TI; Bajel A
Pathology; 2021 Apr; 53(3):312-327. PubMed ID: 33676766
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients.
Elrhman HAEA; El-Meligui YM; Elalawi SM
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e960-e969. PubMed ID: 34376373
[TBL] [Abstract][Full Text] [Related]
15. Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia.
Chiriches C; Khan D; Wieske M; Guillen N; Rokicki M; Guy C; Wilson M; Heesom KJ; Ottmann OG; Ruthardt M
Ann Hematol; 2022 Oct; 101(10):2179-2193. PubMed ID: 35941390
[TBL] [Abstract][Full Text] [Related]
16. Secondary acquisition of BCR-ABL1 fusion in de novo GATA2-MECOM positive acute myeloid leukemia with subsequent emergence of a rare KMT2A-ASXL2 fusion.
Blackburn PR; Huang L; Dalovisio A; Pitel BA; Chen D; Oliveira JL; Wood AJ; Smadbeck JB; Johnson SH; Vasmatzis G; Haferlach C; Greipp PT; Hoppman NL; Ketterling RP; Baughn LB; Peterson JF
Cancer Genet; 2020 Feb; 241():67-71. PubMed ID: 31902694
[TBL] [Abstract][Full Text] [Related]
17. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
[TBL] [Abstract][Full Text] [Related]
18.
Panagopoulos I; Gorunova L; Torkildsen S; Tjønnfjord GE; Micci F; Heim S
Cancer Genomics Proteomics; 2017; 14(6):437-443. PubMed ID: 29109093
[TBL] [Abstract][Full Text] [Related]
19. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
Weisberg E; Banerji L; Wright RD; Barrett R; Ray A; Moreno D; Catley L; Jiang J; Hall-Meyers E; Sauveur-Michel M; Stone R; Galinsky I; Fox E; Kung AL; Griffin JD
Blood; 2008 Apr; 111(7):3723-34. PubMed ID: 18184863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
